Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil H Shear

Showing results (151-160 of 192) with videos related to

Pageof 20
Sort By:
Journal of Drugs in Dermatology : JDD|August 4, 2012
A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of responseHarvey Lui, Wayne Gulliver, Jerry Tan, et al.
Skin Appendage Disorders|December 5, 2019
Monotherapy for Alopecia Areata: A Systematic Review and Network Meta-AnalysisAditya K Gupta, Jessie L Carviel, Kelly A Foley, et al.
SAGE Open Medical Case Reports|August 25, 2022
Reactive infectious mucocutaneous eruption - repeat etanercept after intravenous immunoglobulin: A case reportRochelle Tonkin, Malika Ladha, Nicole Johnson, et al.
Drug Safety|May 1, 2019
The 10th International Congress on Cutaneous Adverse Drug Reactions, Shimane, Japan, 2018: Focus on New DiscoveriesCristina Olteanu, Neil H Shear, Eishin Morita, et al.
Drug Safety|May 3, 2014
The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: focus on severe cutaneous adverse reactionsRoni P Dodiuk-Gad, Wen-Hung Chung, Chih-Hsun Yang, et al.
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Update on alefacept safetyDenise Wexler, Gordon Searles, Ian Landells, et al.
The Journal of Allergy and Clinical Immunology|March 19, 2002
Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactionsN Franklin Adkinson, David Essayan, Rebecca Gruchalla, et al.
Journal of the American Academy of Dermatology|February 25, 2021
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial dataNeil H Shear, Keith A Betts, Ahmed M Soliman, et al.
Epilepsia|March 7, 2014
Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactionsUrsula Amstutz, Neil H Shear, Michael J Rieder, et al.
Journal of Cutaneous Medicine and Surgery|May 4, 2005
Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004Lyn Guenther, Richard G Langley, Neil H Shear, et al.
Pageof 20

Showing results (151-160 of 192) with videos related to

Sort By:
Pageof 20
Journal of Drugs in Dermatology : JDD|August 4, 2012
A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of responseHarvey Lui, Wayne Gulliver, Jerry Tan, et al.
Skin Appendage Disorders|December 5, 2019
Monotherapy for Alopecia Areata: A Systematic Review and Network Meta-AnalysisAditya K Gupta, Jessie L Carviel, Kelly A Foley, et al.
SAGE Open Medical Case Reports|August 25, 2022
Reactive infectious mucocutaneous eruption - repeat etanercept after intravenous immunoglobulin: A case reportRochelle Tonkin, Malika Ladha, Nicole Johnson, et al.
Drug Safety|May 1, 2019
The 10th International Congress on Cutaneous Adverse Drug Reactions, Shimane, Japan, 2018: Focus on New DiscoveriesCristina Olteanu, Neil H Shear, Eishin Morita, et al.
Drug Safety|May 3, 2014
The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: focus on severe cutaneous adverse reactionsRoni P Dodiuk-Gad, Wen-Hung Chung, Chih-Hsun Yang, et al.
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Update on alefacept safetyDenise Wexler, Gordon Searles, Ian Landells, et al.
The Journal of Allergy and Clinical Immunology|March 19, 2002
Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactionsN Franklin Adkinson, David Essayan, Rebecca Gruchalla, et al.
Journal of the American Academy of Dermatology|February 25, 2021
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial dataNeil H Shear, Keith A Betts, Ahmed M Soliman, et al.
Epilepsia|March 7, 2014
Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactionsUrsula Amstutz, Neil H Shear, Michael J Rieder, et al.
Journal of Cutaneous Medicine and Surgery|May 4, 2005
Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004Lyn Guenther, Richard G Langley, Neil H Shear, et al.
Pageof 20